Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Cite this article
Heart Failure University 2015: Presentation Summaries
1 Cardiology Division, Massachusetts General Hospital, Boston, MA
2 Cardiology Division, Brigham and Women’s Hospital, Boston, MA
3 Institute for Clinical Research, Boston, MA
Rev. Cardiovasc. Med. 2016, 17(S1), 1–8; https://doi.org/10.3909/ricm17S1S0001
Published: 20 January 2016
Heart failure (HF) is a chronic and complex disease entity with an enormous morbidity and mortality. Many of the therapies used in the management of HF were developed decades ago, but recently more novel monitoring and therapeutic strategies have emerged. The employment of these strategies may reduce morbidity and mortality in patients with HF. This article reviews the epidemiology of HF and some of the novel strategies developed to assess risk and monitor these challenging patients. It also discusses the evidence behind some of the newer treatments available that are recently included in the HF management guidelines. Various devices used in the treatment of HF, some of which remain investigational, are also discussed. Novel strategies for remote monitoring and new pharmacologic therapies may be useful in improving morbidity and mortality in patients with HF.
Guideline-directed medical therapy